Related Experiment Video
Updated: Sep 15, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Microglial dysfunction in Alzheimer's disease: Mechanisms, emerging therapies, and future directions
Mahir Azmal1, Jibon Kumar Paul1, Fatema Sultana Prima1
1Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh.
Abstract:
Alzheimer's disease (AD) is a severe neurodegenerative condition characterized by progressive cognitive decline and behavioral changes. These symptoms are primarily driven by the accumulation of amyloid-beta (Aβ) plaques, tau tangles, and persistent neuroinflammation. Microglia, the brain's resident immune cells, play a crucial role in the disease's progression. Initially, these cells protectively respond to Aβ deposits, working to clear plaques and support neuronal health. However, prolonged activation of microglia leads to a transition from a neuroprotective state to a pro-inflammatory one, ultimately contributing to neuronal damage and worsening disease progression. This review explores the molecular mechanisms responsible for microglial dysfunction in AD, with a particular emphasis on key inflammatory pathways, including NF-κB, MAPK, and TLR4 signaling. These pathways drive the release of pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6, which further amplify neuroinflammation, disrupt synaptic plasticity, and contribute to neuronal loss. Additionally, emerging therapeutic strategies aimed at modulating microglial activity to reduce neuroinflammation and enhance Aβ clearance are examined. A key focus is placed on the future of AD research, emphasizing the importance of longitudinal studies to gain a deeper understanding of how microglia contribute to disease progression over time. The review also highlights the potential of personalized medicine, which seeks to tailor treatments based on an individual's unique genetic and environmental risk factors. Notably, genetic predispositions such as the APOE4 allele, along with environmental influences like air pollution and chronic infections, are identified as significant modulators of microglial activity. Given the complexity of AD, a comprehensive, multi-faceted approach will be essential for advancing research and developing more effective therapeutic interventions.
Insights
Microglia, the brain's immune cells, shift from protective to harmful roles in Alzheimer's disease (AD). Targeting their inflammatory pathways offers new therapeutic avenues for AD treatment.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Alzheimer's disease (AD) involves amyloid-beta (Aβ) plaques, tau tangles, and neuroinflammation.
- Microglia, the brain's immune cells, are central to AD pathogenesis.
- Microglial dysfunction transitions from neuroprotection to detrimental inflammation.
Purpose of the Study:
- To explore molecular mechanisms of microglial dysfunction in AD.
- To emphasize key inflammatory pathways (NF-κB, MAPK, TLR4) driving neuroinflammation.
- To examine therapeutic strategies targeting microglial activity.
Main Methods:
- Review of molecular mechanisms in microglial dysfunction.
- Analysis of inflammatory signaling pathways (NF-κB, MAPK, TLR4).
- Examination of emerging therapeutic strategies for AD.
Main Results:
- Prolonged microglial activation promotes a pro-inflammatory state.
- Inflammatory pathways release cytokines (IL-1β, TNF-α, IL-6), exacerbating neuroinflammation.
- Genetic (APOE4) and environmental factors modulate microglial activity.
Conclusions:
- Modulating microglial activity is a promising therapeutic strategy for AD.
- Longitudinal studies are crucial for understanding microglial roles in disease progression.
- Personalized medicine approaches are essential for effective AD treatment.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment

